From owner-ports-jp@jp.FreeBSD.org Sat Jan 20 02:36:01 2007
Received: (from daemon@localhost)
	by castle.jp.FreeBSD.org (8.11.6p2+3.4W/8.11.3) id l0JHa1b64014;
	Sat, 20 Jan 2007 02:36:01 +0900 (JST)
	(envelope-from owner-ports-jp@jp.FreeBSD.org)
Received: from pool-71-101-252-249.tampfl.dsl-w.verizon.net (pool-71-101-252-249.tampfl.dsl-w.verizon.net [71.101.252.249])
	by castle.jp.FreeBSD.org (8.11.6p2+3.4W/8.11.3) with ESMTP/inet id l0JHZvw64007;
	Sat, 20 Jan 2007 02:35:58 +0900 (JST)
	(envelope-from usthyme's@aakcpa.com)
Received: from 4.79.181.18 (HELO mx1.biz.mail.yahoo.com)
     by jp.freebsd.org with esmtp (1?*2FLV8;ZR /E9U<7)
     id V-Q@)--S7U=)(-5F
     for rushani@jp.freebsd.org; Fri, 19 Jan 2007 17:35:46 +0300
From: "Phillip Steele" <usthyme's@aakcpa.com>
To: <rushani@jp.FreeBSD.org>
Message-ID: <01c73bf0$40c87fa0$6c822ecf@usthyme's>
MIME-Version: 1.0
Content-Type: text/plain;
	charset="iso-8859-2"
Content-Transfer-Encoding: 7bit
X-Priority: 3 (Normal)
X-MSMail-Priority: Normal
X-Mailer: Microsoft Office Outlook, Build 11.0.6353
X-MimeOLE: Produced By Microsoft MimeOLE V5.50.4927.1200
Thread-Index: Aca6Q2T)47D(+6)1/8UAZ*@4U71-KP==
Reply-To: ports-jp@jp.FreeBSD.org
Precedence: list
Date: Fri, 19 Jan 2007 17:35:46 +0300
X-Sequence: ports-jp 27490
Subject: [ports-jp 27490] {subj190107}
Sender: owner-ports-jp@jp.FreeBSD.org
X-Originator: usthyme's@aakcpa.com
X-Distribute: distribute version 2.1 (Alpha) patchlevel 24e+060209

No more scam or bullshit companies.
Look at charts and ask your broker about:

Ventana Medical Systems

Ventana Receives FDA Approval on Pathway

Thursday January 18, 10:08 am ET
Ventana Medical Systems Receives FDA Approval for Breast Cancer Detection Test

TUCSON, Ariz. (AP) -- Ventana Medical Systems Inc., a maker of tissue and slide preparation systems used in drug development, said Wednesday it received Food and Drug Administration approval on a new antibody.
The company received the approval for its Pathway Her-2/neu (4B5) Rabbit Monoclonal Antibody as an aid in assessing breast cancer patients being considered for treatment with Herceptin. It is also approved for use on the Ventana Image Analysis System.
Herceptin is a cancer treatment made by Genentech Inc. It targets HER-2, which causes breast cancer cells to grow more rapidly. The approved Pathway antibody is intended to detect the presence of the HER-2 antigen.

Get in before most investors hear about this awesome news!  VMSI has just made an announcement which, once the investment community hears about it, is going to send the issue rise!  Read on to find why we are so excited!


